About Cardiolipin synthase (CMP-forming)
Cardiolipin synthase (CMP-forming) (CRLS1) is a protein
from Homo sapiens identified by UniProt accession
Q9UJA2, 301 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | Cardiolipin synthase (CMP-forming) |
|---|
| UniProt accession | Q9UJA2 |
|---|
| Gene | CRLS1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 301 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (87)
Diseases linked to this target (Open Targets).
- Parkinson disease · score 0.29
- glioblastoma multiforme · score 0.19
- heel bone mineral density · score 0.09
- bone quantitative ultrasound measurement · score 0.09
- colorectal cancer · score 0.08
- body fat distribution · score 0.08
- Agents acting on the renin-angiotensin system use measurement · score 0.08
- bone density · score 0.07
- QRS duration · score 0.07
- appendicular lean mass · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UJA2-F1 | alphafold | PREDICTED | 69.01 | — |
Amino-acid sequence (301 residues)
MLALRVARGS WGALRGAAWA PGTRPSKRRA CWALLPPVPC CLGCLAERWR LRPAALGLRL PGIGQRNHCS GAGKAAPRPA AGAGAAAEAP GGQWGPASTP SLYENPWTIP NMLSMTRIGL APVLGYLIIE EDFNIALGVF ALAGLTDLLD GFIARNWANQ RSALGSALDP LADKILISIL YVSLTYADLI PVPLTYMIIS RDVMLIAAVF YVRYRTLPTP RTLAKYFNPC YATARLKPTF ISKVNTAVQL ILVAASLAAP VFNYADSIYL QILWCFTAFT TAASAYSYYH YGRKTVQVIK D
Explore Cardiolipin synthase (CMP-forming) with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets